Eptinezumab study for the acute treatment of migraine status in the ED

Dosing: single dose 300mg IV over 30minutes

(no other acute medication or IVF allowed for 2 hours post infusion unless medical urgency)

Questionnaire to be completed by ED physician

2 HR POST TREATMENT RESPONSE

(once completed, pls leave in Dr Florea's box)

If assessment at 2 hours post infusion was not possible for you, please indicate approximately how long after the infusion you assessed the patient:

		-	-		
1)	Circle patient level of pain inten	sity: SEVERE	MODERATE	MILD	ABSENT
2)	What is the patient's subjective response to their treatment with eptinezumab:				
	□ VERY MUCH BETTER □MUCH BETTER	□A LITTLE BET □NO CHANGE □A LITTLE WO	Ξ		MUCH WORSE /ERY MUCH ORSE
3)	Is the patient's most bothersome migraine-associated symptom from baseline (nausea, photophobia or phonophobia) now absent? YES NO				
4)	Did your patient require additional rescue medication post infusion? YES NO				
5)	Did you consult a neurologist in the ED due to non response? YES NO				
ne er	If the patient wishes to have a follow-up at the CHUM headache clinic in 3 months, advise the patient to immediately install the Canadian Migraine Tracker application (green and purple logo-free installation) to monitor their headaches until their first appointment. If they prefer a paper format, please print and hand them a paper calendar to fill our migrainecanada.org/printable-migraine-diary-templates/				

Sign the pre completed referral and leave in Dr Florea's box.